These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 16620364)

  • 1. Tolerability and safety of fluvoxamine and other antidepressants.
    Westenberg HG; Sandner C
    Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of depressed pregnant women by selective serotonin reuptake inhibitors: risk for the foetus and the newborn].
    Favrelière S; Nourrisson A; Jaafari N; Pérault Pochat MC
    Encephale; 2010 Jun; 36 Suppl 2():D133-8. PubMed ID: 20513456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.
    Anderson IM
    J Affect Disord; 2000 Apr; 58(1):19-36. PubMed ID: 10760555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
    Bailly D
    Presse Med; 2006 Oct; 35(10 Pt 2):1507-15. PubMed ID: 17028514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fluoxetine: an update of its use in major depressive disorder in adults].
    Gourion D; Perrin E; Quintin P
    Encephale; 2004; 30(4):392-9. PubMed ID: 15597466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine versus other anti-depressive agents for depression.
    Omori IM; Watanabe N; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD006114. PubMed ID: 20238342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
    Stahl SM; Entsuah R; Rudolph RL
    Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of the new antidepressants.
    Nelson JC
    J Clin Psychiatry; 1997; 58 Suppl 6():26-31. PubMed ID: 9227670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality?
    Hall WD; Lucke J
    Aust N Z J Psychiatry; 2006; 40(11-12):941-50. PubMed ID: 17054562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
    Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
    Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression.
    Mace S; Taylor D
    Expert Opin Pharmacother; 2000 Jul; 1(5):917-33. PubMed ID: 11249500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects.
    Grassi B; Gambini O; Scarone S
    Pharmacopsychiatry; 1995 May; 28(3):93-4. PubMed ID: 7568371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?
    Ashford JJ
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():27-31. PubMed ID: 7622820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
    Thase ME; Entsuah AR; Rudolph RL
    Br J Psychiatry; 2001 Mar; 178():234-41. PubMed ID: 11230034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
    de Silva VA; Hanwella R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):8-16. PubMed ID: 21971532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
    Sussman N; Ginsberg DL; Bikoff J
    J Clin Psychiatry; 2001 Apr; 62(4):256-60. PubMed ID: 11379839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.